# Low-dose Rifaximin in the Treatment of Covert Hepatic Encephalopathy

> **NCT03077217** · PHASE4 · COMPLETED · sponsor: **Shanghai Changzheng Hospital** · enrollment: 40 (actual)

## Conditions studied

- Covert Hepatic Encephalopathy

## Interventions

- **DRUG:** Rifaximin

## Key facts

- **NCT ID:** NCT03077217
- **Lead sponsor:** Shanghai Changzheng Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-01
- **Primary completion:** 2020-05-31
- **Final completion:** 2020-05-31
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2021-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03077217

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03077217, "Low-dose Rifaximin in the Treatment of Covert Hepatic Encephalopathy". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03077217. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*